Treatment of adult ALL patients with third-generation CD19-directed CAR T cells: results of a pivotal trial

[1]  Kiya W. Govek,et al.  Single-cell antigen-specific landscape of CAR T infusion product identifies determinants of CD19-positive relapse in patients with ALL , 2022, Science advances.

[2]  Harald J. Maier,et al.  Next-Generation Sequencing of Minimal Residual Disease for Predicting Relapse after Tisagenlecleucel in Children and Young Adults with Acute Lymphoblastic Leukemia , 2021, Blood cancer discovery.

[3]  S. Steinberg,et al.  Blinatumomab Nonresponse and High-Disease Burden Are Associated With Inferior Outcomes After CD19-CAR for B-ALL , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  G. Marcucci,et al.  Extramedullary disease relapse and progression after blinatumomab therapy for treatment of acute lymphoblastic leukemia , 2021, Cancer.

[5]  H. Kotani,et al.  4-1BB and optimized CD28 co-stimulation enhances function of human mono-specific and bi-specific third-generation CAR T cells , 2021, Journal for ImmunoTherapy of Cancer.

[6]  V. Beneš,et al.  Single-cell proteo-genomic reference maps of the hematopoietic system enable the purification and massive profiling of precisely defined cell states , 2021, Nature Immunology.

[7]  R. Houot,et al.  KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study , 2021, The Lancet.

[8]  E. Clappier,et al.  Determinants of CD19-positive vs CD19-negative relapse after tisagenlecleucel for B-cell acute lymphoblastic leukemia , 2021, Leukemia.

[9]  Givanna H. Putri,et al.  Integration, exploration, and analysis of high‐dimensional single‐cell cytometry data using Spectre , 2021, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

[10]  A. Logan,et al.  KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results. , 2021, Blood.

[11]  Thomas Myles Ashhurst,et al.  Integration, exploration, and analysis of high-dimensional single-cell cytometry data using Spectre , 2020, bioRxiv.

[12]  P. Dreger,et al.  Side-effect management of chimeric antigen receptor (CAR) T-cell therapy. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

[13]  Michael R. Green,et al.  Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas , 2020, Nature Medicine.

[14]  A. Ho,et al.  Feasibility and safety of CD19 CAR T cell treatment for B-cell lymphoma relapse after allogeneic hematopoietic stem cell transplantation. , 2020, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[15]  B. Dai,et al.  Tumor-infiltrating CD39+CD8+ T cells determine poor prognosis and immune evasion in clear cell renal cell carcinoma patients , 2020, Cancer Immunology, Immunotherapy.

[16]  P. Dreger,et al.  Optimized Assessment of qPCR-Based Vector Copy Numbers as a Safety Parameter for GMP-Grade CAR T Cells and Monitoring of Frequency in Patients , 2020, Molecular therapy. Methods & clinical development.

[17]  Yvan Saeys,et al.  CytoNorm: A Normalization Algorithm for Cytometry Data , 2019, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

[18]  A. Ho,et al.  Treatment of patients with relapsed or refractory CD19+ lymphoid disease with T lymphocytes transduced by RV-SFG.CD19.CD28.4-1BBzeta retroviral vector: a unicentre phase I/II clinical trial protocol , 2019, BMJ Open.

[19]  L. Sellner,et al.  Improvement of in vitro potency assays by a resting step for clinical-grade chimeric antigen receptor engineered T cells. , 2019, Cytotherapy.

[20]  D. Maloney,et al.  Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy. , 2019, Blood.

[21]  J. Schachter,et al.  Early and late hematologic toxicity following CD19 CAR-T cells , 2019, Bone Marrow Transplantation.

[22]  S. Grupp,et al.  ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. , 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[23]  Hao Liu,et al.  In Vivo Fate and Activity of Second- versus Third-Generation CD19-Specific CAR-T Cells in B Cell Non-Hodgkin's Lymphomas. , 2018, Molecular therapy : the journal of the American Society of Gene Therapy.

[24]  Leland McInnes,et al.  UMAP: Uniform Manifold Approximation and Projection , 2018, J. Open Source Softw..

[25]  M. Höglund,et al.  A Phase I/IIa Trial Using CD19-Targeted Third-Generation CAR T Cells for Lymphoma and Leukemia , 2018, Clinical Cancer Research.

[26]  Mark D. Robinson,et al.  diffcyt: Differential discovery in high-dimensional cytometry via high-resolution clustering , 2018, Communications Biology.

[27]  Hans Bitter,et al.  Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia , 2018, Nature Medicine.

[28]  H. Dombret,et al.  Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia. , 2018, Blood.

[29]  K. Davis,et al.  Tisagenlecleucel in Children and Young Adults with B‐Cell Lymphoblastic Leukemia , 2018, The New England journal of medicine.

[30]  Mithat Gonen,et al.  Long‐Term Follow‐up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia , 2018, The New England journal of medicine.

[31]  M. Jin,et al.  Micromolar affinity CAR T cells to ICAM-1 achieves rapid tumor elimination while avoiding systemic toxicity , 2017, Scientific Reports.

[32]  S. Riddell,et al.  Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults. , 2017, Blood.

[33]  B. Becher,et al.  CyTOF workflow: differential discovery in high-throughput high-dimensional cytometry datasets , 2017, F1000Research.

[34]  Hao Liu,et al.  Redirecting T Cells to Glypican-3 with 4-1BB Zeta Chimeric Antigen Receptors Results in Th1 Polarization and Potent Antitumor Activity , 2017 .

[35]  N. Gökbuget.  Treatment of older patients with acute lymphoblastic leukemia. , 2016, Hematology. American Society of Hematology. Education Program.

[36]  Giovanni Martinelli,et al.  International reference analysis of outcomes in adults with B-precursor Ph-negative relapsed/refractory acute lymphoblastic leukemia , 2016, Haematologica.

[37]  Daniel Li,et al.  CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients. , 2016, The Journal of clinical investigation.

[38]  Ash A. Alizadeh,et al.  Abstract PR09: The prognostic landscape of genes and infiltrating immune cells across human cancers , 2015 .

[39]  M. Sadelain,et al.  Structural Design of Engineered Costimulation Determines Tumor Rejection Kinetics and Persistence of CAR T Cells. , 2015, Cancer cell.

[40]  P. Klenerman,et al.  CD39 Expression Identifies Terminally Exhausted CD8+ T Cells , 2015, PLoS pathogens.

[41]  D. Maloney,et al.  Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo , 2015, Leukemia.

[42]  R. Kaplan,et al.  4-1BB Costimulation Ameliorates T Cell Exhaustion Induced by Tonic Signaling of Chimeric Antigen Receptors , 2015, Nature Medicine.

[43]  Matthew J. Frigault,et al.  Identification of Chimeric Antigen Receptors That Mediate Constitutive or Inducible Proliferation of T Cells , 2015, Cancer Immunology Research.

[44]  C Barbui,et al.  What is the European Medicines Agency? , 2012, Epidemiology and Psychiatric Sciences.

[45]  Michael J. Zilliox,et al.  Phenotype, Function, and Gene Expression Profiles of Programmed Death-1hi CD8 T Cells in Healthy Human Adults , 2011, The Journal of Immunology.

[46]  M. Sadelain,et al.  Chimeric antigen receptors combining 4-1BB and CD28 signaling domains augment PI3kinase/AKT/Bcl-XL activation and CD8+ T cell-mediated tumor eradication. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[47]  J. Wagner,et al.  4-1BB and CD28 signaling plays a synergistic role in redirecting umbilical cord blood T cells against B-cell malignancies. , 2010, Human gene therapy.

[48]  D. Campana,et al.  Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.

[49]  I. Pastan,et al.  Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains , 2009, Proceedings of the National Academy of Sciences.

[50]  C. June,et al.  4-1BB Is Superior to CD28 Costimulation for Generating CD8+ Cytotoxic Lymphocytes for Adoptive Immunotherapy1 , 2007, The Journal of Immunology.

[51]  P. Rossini,et al.  Expression of ectonucleotidase CD39 by Foxp3+ Treg cells: hydrolysis of extracellular ATP and immune suppression. , 2007, Blood.

[52]  V. Kuchroo,et al.  Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression , 2007, The Journal of experimental medicine.

[53]  J. Mehta,et al.  Long term disease-free survival in acute leukemia patients recovering with increased γδ T cells after partially mismatched related donor bone marrow transplantation , 2007, Bone Marrow Transplantation.

[54]  J. Radich,et al.  End points to establish the efficacy of new agents in the treatment of acute leukemia. , 2007, Blood.

[55]  Sigrid Stroobants,et al.  Revised response criteria for malignant lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[56]  David D. Smith,et al.  CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells. , 2006, Cancer research.

[57]  M. Brenner,et al.  Addition of the CD28 signaling domain to chimeric T-cell receptors enhances chimeric T-cell resistance to T regulatory cells , 2006, Leukemia.

[58]  M. Cairo,et al.  Tumour lysis syndrome: new therapeutic strategies and classification , 2004, British journal of haematology.

[59]  A. Gee,et al.  Rapid Communication: Increased Frequency of TCRγδ+ T Cells in Disease-Free Survivors Following T Cell-Depleted, Partially Mismatched, Related Donor Bone Marrow Transplantation for Leukemia , 1996 .

[60]  R. Storb,et al.  Histopathology of graft-vs.-host reaction (GvHR) in human recipients of marrow from HL-A-matched sibling donors. , 1974, Transplantation proceedings.

[61]  Robinson.  CyTOF workflow: Differential discovery in high-throughput , 2019 .

[62]  Malgorzata Nowicka,et al.  CyTOF workflow: differential discovery in high-throughput high-dimensional cytometry datasets. , 2017, F1000Research.

[63]  H. Kantarjian,et al.  Adult Acute Lymphoblastic Leukemia. , 2016, Mayo Clinic proceedings.

[64]  R. Larson,et al.  Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. , 2015, The Lancet. Oncology.

[65]  J. Mehta,et al.  Long term disease-free survival in acute leukemia patients recovering with increased gammadelta T cells after partially mismatched related donor bone marrow transplantation. , 2007, Bone marrow transplantation.

[66]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..

[67]  A. Gee,et al.  Increased frequency of TCR gamma delta + T cells in disease-free survivors following T cell-depleted, partially mismatched, related donor bone marrow transplantation for leukemia. , 1996, Journal of hematotherapy.

[68]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .